Enovis Corp (ENOV) Peer Comparison

$25.09

$0.26 (1.05%)

As on 28-Aug-2026 13:40EDT

Market cap

$1,510 Mln

Revenue (TTM)

$2,297 Mln

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Edit

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	1,510	12,753	10,906	10,222	9,762
Revenue ($ Mln)	2,297	1,505	613	785	2,589
Net Profit ($ Mln)	-1,101.69	160.59	-188.05	41.54	222.40
Net Margin (%)	-47.97	10.67	-30.68	5.29	8.59
RoE (%)	-74.33	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	1.03	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	2,296.60	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	977.63	483.98	127.96	384.30	1,245.50
Gross Profit	1,345.26	942.44	393.22	347.62	1,343.60
Operating Expenses	1,224.00	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	94.98	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-1,068.32	203.83	-192.83	52.15	350.40
Provision for Tax	30.81	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-1,101.69	160.59	-188.05	41.54	222.40
Minority Interest	-0.84	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	1,477.07	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	-0.84	0.00	0.00	0.00	0.00
Non-Current Liabilities	1,674.91	210.18	135.71	705.49	2,116.80
Current Liabilities	612.05	233.78	102.33	132.66	961.30
Total Liabilities	3,834.74	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	2,551.44	630.60	404.74	1,749.63	7,231.50
Current Assets	1,214.69	1,344.12	515.78	1,200.55	3,020.50
Total Assets	3,834.74	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	1,369.05	212.71	102.84	690.94	1,203.70
Net Current Assets	602.64	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	217.29	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-179.37	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-52.40	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-34.65	11.76	-22.53	1.79	8.98
ROE (%)	-74.33	10.86	-28.10	1.97	3.04
ROA (%)	-22.11	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-44.10	13.63	-30.58	9.87	-5.99
Net Margin (%)	-47.97	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	4.89	17.55	41.55	16.49	1.37
EBIT Growth (%)	-33.13	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	-33.12	8.72	-102.66	400.42	-30.32
EPS Growth (%)	-36.14	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-43.51	17.33	-12.65	2.16	2.19

Valuation Ratios

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-1.28	68.93	-34.59	189.42	--
Price / Book Value	1.02	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.44	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.84	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.04	0.01	0.00	0.01	0.06
Current Ratio	1.98	5.75	5.04	9.05	3.14
Quick Ratio	1.00	3.86	4.46	7.64	2.33
Interest Coverage	-18.23	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Enovis Corp (ENOV)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	19.24	12.65	22.67	20.09	17.06
Asset Turnover	0.46	0.74	0.59	0.26	0.24
Receivable days	69.04	46.54	60.95	72.41	65.39
Inventory Days	228.89	331.92	193.84	146.53	221.09
Payable days	74.17	26.16	60.19	29.05	37.02
Cash Conversion Cycle	223.76	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly